Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A
Clinical and Molecular Hepatology · 01.10.2025 · 31 (4) · 1333-1354
DOI: 10.3350/cmh.2024.1041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2025. Verfasst von Yuli Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Central Laboratory of Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carnitine O-Palmitoyltransferase, Fatty Liver, Suppressor of Cytokine Signaling 3 Protein, Ubiquitin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Natural Science Foundation of Shanghai.
Abstract (Originalsprache)
Background/Aims: Excessive lipid accumulation in hepatocytes is a critical cause of metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Ankyrin repeat and SOCS box protein 3 (ASB3) is an E3 ubiquitin ligase that mediates diverse disease processes; however, the direct substrates of ASB3 in lipid metabolism and its role in MASLD remain unexplored.
Methods
We generated ASB3 knockout mice fed a high-fat diet to induce MASLD. Oxygen consumption and fatty acid oxidation (FAO) were used to assess lipid metabolism. LC-MS/MS and IP were used to verify the ASB3 target protein. Correlation analysis was conducted on the cohort of MASLD patients vs. the control group.
Results
Loss of the ASB3 E3 ubiquitin ligase in hepatocytes strengthens mitochondrial FAO, thereby influencing energy consumption to decrease triglyceride storage and lipid accumulation. Quantitative lysine ubiquitination proteomics revealed that ASB3 directly mediated the ubiquitin levels at two sites (K180 and K639) in carnitine palmitoyl transferase 1A (CPT1A), a rate-limiting enzyme of FAO, to induce CPT1A degradation. Moreover, both constitutive and hepatocyte-specific ASB3 knockout enhance FAO and delay lipid accumulation, liver steatosis, and MASLD progression in a CPT1A-dependent manner. Hepatic ASB3 deficiency also delays fibrosis in MASLD. Analysis of public databases and liver tissue samples from MASLD patients revealed that ASB3 was highly expressed in MASLD patients and was negatively correlated with CPT1A.
Conclusions
Our study reveals the key roles of ASB3 in the development of MASLD and suggests a novel therapeutic potential for MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Central Laboratory of Huashan Hospital, Fudan University, Shanghai, China.
- Department of Immunology and Department of Anatomy, Histoembryology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Anatomy, Histoembryology, School of Basic Medical Sciences, Fudan University, Shanghai Medical College, Shanghai, China.
- Division of Hematology, The Ohio State University Wexner Medical Center, the James Cancer Hospital, Columbus, OH, USA.
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Natural Science Foundation of Shanghai
Zitieren
APA
Lin, Y., Hou, W., Ge, M., Wu, Z., Huang, L., Liu, H., Zhang, W., Deng, X., Wang, L., Guan, M., Song, C., Wang, Z., & Yang, D. (2025). Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A. Clinical and Molecular Hepatology, 31(4), 1333-1354. https://doi.org/10.3350/cmh.2024.1041
Vancouver
Lin Y, Hou W, Ge M, Wu Z, Huang L, Liu H, et al. Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A. Clinical and Molecular Hepatology. 2025;31(4):1333-1354. doi:10.3350/cmh.2024.1041
BibTeX
@article{Lin2025,
author = {Lin, Yuli and Hou, Wulei and Ge, Mengxiao and Wu, Zhihao and Huang, Linlin and Liu, Haoye and Zhang, Wenli and Deng, Xiyu and Wang, Lanxin and Guan, Ming and Song, Chunhua and Wang, Zuoyun and Yang, Dongqin},
title = {Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {4},
pages = {1333--1354},
doi = {10.3350/cmh.2024.1041}
}
EUVIMED